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Two types of CRH receptors mediate the diverse biological functions of CRH and CRH-related
peptides. The type 1CRH-R (CRH-R1) is extensively targetedbypre-mRNA splicingmechanisms that
give rise tomultiplemRNA splice variants. RT-PCR amplification of CRH-R1 sequences from human
myometrium yielded cDNAs that encode a novel CRH-R1 splice variant with structural character-
istics identical with CRH-R1 except a 14-amino acid deletion in the seventh transmembrane do-
main characteristic of the CRH-R1d. Transient expression of the hybrid CRH-R1 variant (CRH-R1/d)
in human embryonic kidney 293 cells revealed primarily intracellular expression, although some
plasma membrane protein expression was also detectable. CRH bound to CRH-R1/d with affinity
comparablewith theCRH-R1; however, itwasunable to stimulateadenylyl cyclaseorother second
messengers. Using a semiquantitative RT-PCR assay, CRH-R1/d mRNA transcript was detected in
human pregnant, but not nonpregnant, myometrium as early as 31wk of gestation. Furthermore,
in human pregnant myometrial cells, the relative expression of CRH-R1 and CRH-R1/d mRNA
appeared tobe regulatedby steroids; CRH-R1/dmRNAexpressionwas increasedby estradiol-17,
whereas CRH-R1 mRNA levels were increased by progesterone. Progesterone also substantially
increased CRH-R1 mRNA levels and cellular responsiveness to CRH as determined by increased
agonist binding and cAMP production as well as resistance to CRH-R heterologous desensitization
by phorbol esters. These results provide novel evidence for distinct patterns of CRH-R1 splicing and
identify specific steroid-mediated regulation of CRH-R1 variant expression, which might be im-
portant for modulating CRH actions during human pregnancy and labour. (Endocrinology 151:
4959–4968, 2010)
During humanpregnancy, the placenta synthesizes andsecretes CRH into the maternal circulation. This pla-
cental CRH might act to control a placental clock, which
is active from the early stages of pregnancy anddetermines
the length of the gestation and the timing of parturition
and delivery (1). The biological roles of CRHduring preg-
nancyare still not fullyunderstood; thepresenceof specific
CRH receptors (CRH-Rs) in many tissues of the fetoma-
ternal unit such as the placenta, myometrium, decidua,
and fetal adrenals, suggests that CRH might target these
tissues to exert important functions (2). For example, the
expression of functional CRH-R and locally produced
CRHandCRH-related peptides such as urocortin (Ucn)-1
and Ucn2 in the myometrium (3–6), which regulate
smooth muscle contractility, suggests a role in the devel-
opmentof humanparturitionbypreventing thepremature
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activation of the myometrium and thus coordinating the
transition of the uterus from a state of relaxation to one of
contraction (7).
The actions of CRH in target tissues are mediated via
binding to and activation of specific seven-transmem-
brane domain (TMD) G protein-coupled receptors
(GPCRs). To date, two distinct CRH receptor subtypes
(R1 andR2) have been identified inmammals (8, 9). These
receptors belong to the Secretin family of GPCRs (recep-
tors for brain-gut neuropeptides) and exhibit a diverse
alternative pre-mRNA splicing pattern that appears to be
conserved among members of the Secretin family of
GPCRs (10). The fully functional CRH-R1, termedCRH-
R1, is a415-aminoacidprotein thatbindsbothCRHand
Ucn1 and activates multiple G proteins and downstream
effectors in a tissue-dependent manner (11, 12). In the
human myometrium, as well as in other tissues, multiple
CRH-R1 mRNA splice variants have been identified, in-
cluding the CRH-R1 variant, which contains 29 addi-
tional amino acids in the first intracellular loop (11), and
shows reduced binding affinity for CRH and coupling to
downstream effectors. Another is the CRH-R1d variant
(13)witha14-aminoaciddeletion fromthe seventhTMD,
which does not affect binding affinity but severely impairs
signal transduction characteristics. Although the physio-
logical roles of these receptor variants is poorly under-
stood, recent evidence suggests that they might dampen
CRH cellular responsiveness by acting as decoy receptors
capable of competing with the fully active receptors for
agonist binding and absorbing peptide bioactivity and
also as potential dominant-negative regulators when co-
expressed with the fully active receptors to inhibit down-
stream signaling activity (14). There is also evidence to
suggest that receptor variants like the CRH-R1 exhibit
unique responses to posttranslational regulatory mecha-
nisms such as Ser/Thr kinase-induced receptor phosphor-
ylation (15).
During pregnancy, the expression of the CRH-R1 vari-
ants appears to be dynamically regulated by unknown
mechanisms, and the onset of labor (preterm or term) is
associated with increased transcription of the myometrial
CRH-R1 gene and altered splicing events that down-reg-
ulate the mRNA encoding the CRH-R1 but up-regulate
receptor variants such asCRH-R1d (16, 17). In this study,
we report the cloning and characterization of a novel
cDNA from human pregnant but not nonpregnant myo-
metrial RNA that encodes a novel spliced variant of the
human CRH-R1. This CRH-R1 variant contains an elon-
gated first intracellular loop by 29 amino acids similar to
the CRH-R1 together with a deletion of 14 amino acids
from the putative seventh TMD. This hybrid CRH-R1
variant was termed CRH-R1/d. We also characterized
the binding and functional properties of this CRH-R1
variant by overexpression studies in human embryonic
kidney (HEK)-293 cells, and we investigated potential
mechanisms regulating CRH-R1 mRNA variant expres-
sion in human pregnant myometrial cells.
Materials and Methods
Chemicals
Radioiodinated ovine (o) CRH, human/rat CRH, and Ucn1
were obtained from Bachem (United Kingdom) Ltd. (Mersey-
side, UK). Mouse monoclonal vimentin antibody and anti-
mouse IgG-tetramethylrhodamine isothiocyanate conjugated
were obtained from Sigma Aldrich United Kingdom (Poole,
UK). Mouse monoclonal muscle-actin antibody was obtained
fromDakoLtd. (Crawley, UK). Themammalian expression vec-
tor pcDNA3.1() and Lipofectamine were obtained from In-
vitrogen (Paisley, UK). CRH-R1 antibody (polyclonal antibody
raised against a peptide mapping at the C terminus of human
CRH-R1) was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Phospho-ERK1/2 (Thr202/Tyr204), total
ERK2, phospho-(Thr180/Tyr182), and total p38 MAPK anti-
bodies were from Cell Signaling (Chandlers Ford, Hampshire,
UK). Deoxynucleotide triphosphates and the DNA ladder were
purchased from Fermentas Life Sciences (York, UK). Synthetic
oligonucleotide probes and enzymes were purchased from Life
Technologies (Paisley, UK). GeneElute mammalian total RNA
kit and all other chemicalswere purchased fromSigmaChemical
Co. Ltd. (Poole, Dorset, UK).
Experimental subjects and sample preparations
Pregnant myometrial biopsies (n  13) were obtained from
women undergoing elective cesarean section at term (n  7) or
preterm (n 6) before the onset of labor for nonmaternal prob-
lems.Thebiopsy sitewas standardized to theuppermarginof the
lower segment of the uterus in the midline. This provides the
closest approximation to the upper segment of the uterus. Non-
pregnant myometrial tissues (n  6) were obtained from pre-
menopausal controls undergoing hysterectomy for nonmalig-
nant conditions. The nonpregnant myometrial biopsies were
obtained from the same location as the cesarean section myo-
metrial biopsies to avoid possible differences in receptor expres-
sion patterns. The relative content of myometrial and fibrous
tissue in these biopsies was identified by immunostaining using
specific smooth muscle cell and fibroblast markers (actin and
vimentin, respectively). The biopsies were immediately snap fro-
zen in liquid nitrogen and subsequently stored at70Cuntil use
or were processed for myocyte cell culture. Ethical approval was
obtained from the local ethical committee and informed consent
to the study was obtained from all patients.
Preparation of myometrial cell cultures
Myocytes were prepared by enzymatic dispersion as previ-
ously described (17). Briefly, pieces of myometrium were trans-
ferred into DMEM containing collagenase (300 U/ml), deoxyri-
bonuclease (30 U/ml), penicillin (200 U/ml), and streptomycin
(200 mg/ml) and incubated at 37 C for 30 min. After filtration
and centrifugation, cells were suspended in DMEM containing
10% fetal calf serum (FCS), penicillin (100 U/ml), streptomycin
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(100 mg/ml), and Fungizone (2.5 g/ml). The cells were kept at
37 C in a humidified atmosphere of 95% air-5% CO2 until
confluent (2 wk). The purity of myometrial muscle cells was
assessed by immunocytochemical staining. Mouse antihuman
smooth muscle actin-specific monoclonal antibody and peroxi-
dase-conjugated rabbit antimouse antibody were used. The hu-
man fibroblast cells and omission of the primary antibody were
used as negative controls, whereas frozen myometrial tissue was
used as a positive control. To minimize fibroblast contamina-
tion, the myocyte preparation was repurified 48 h before the
experiments using 0.5% trypsin.
To study the effects of steroidhormonesonmyometrialCRH-
R1-spliced variant expression, charcoal-dextran T-70-treated
FCS (Life Technologies) was used, and the pH indicator, phenol
red, was omitted. The hormone-depleted FCS was used in the
same proportions as those described previously. For time-course
experiments, myometrial cells were treated with 0.5–5 M of
estradiol-17 (E2) or progesterone (P4) or both for various time
intervals (0–24 h). At the end of the incubation period, cellswere
collected, pelleted by centrifugation, and stored at 80 C until
RNA extraction.
RNA extraction and semiquantitative RT-PCR
Total RNA was extracted from pregnant and nonpregnant
myometrium tissues ormyometrial cell cultures and reverse tran-
scribed to synthesize cDNA by using RNaseH reverse transcrip-
tase (Life Technologies). Distilled water was used in place of the
cDNA as a negative control for each reaction. The forward
primer (position, bp 434–452; sequence, 5-GGCCAGGCTG-
CACCCATTG-3) was designed to hybridize with a nucleotide
sequence present within exon 6 (which encodes for the 29 amino
acid insert in the first intracellular loop, and it is therefore specific
for the CRH-R1), whereas the reverse primer (position, bp
1315–1334; sequence, 5-TTCGTCAGGTGTCGTCAGAC-3)
designed to hybridize with a nucleotide sequence present within
exon 14 (common to all the CRH-R1 subtypes). The semiquan-
titative RT-PCRmethodwas carried out as previously described
(18). The linearity and reproducibility of the PCR were opti-
mized over a wide range of cycle numbers (n  20–45) with
different amounts of cDNA. In addition, different amounts of in
vitro-transcribed RNA corresponding to the different CRH-R1
cDNA variants cloned in the pBluescript vector (Stratagene, La
Jolla, CA) were used to test potential preferential amplification
of one receptor variant over the other. The PCR was performed
in 25-l reactions using 10 Ci/l [32P]-labeled -dGTP and 5
IU/l TAQ DNA polymerase (Life Technologies). Amplifica-
tions were carried out as follows: an initial denaturation step of
5 min at 94 C, followed by 35 cycles for 35 cycles of 30 sec at 94
C, 1min at 58C, and 1min at 72C, followed by a final extension
at 72 C for 10 min. PCR products were separated by electro-
phoresis on a 6% polyacrylamide gel and the dried gel exposed
to x-ray film (Fuji Photo Film Co. Ltd., Tokyo, Japan) or to a
PhosphorImager screen (Molecular Dynamics, Pharmacia Am-
ershamLife Sciences,LittleChalfont,UK) forquantificationpur-
poses. Radioactivity peaks for each product were determined
using ImageQuant (IQ;Molecular Dynamics, Pharmacia Amer-
sham Life Sciences).
Real-time RT-PCR
Real-time, one-step PCR for CRH-R1 and CRH-R1
mRNA (271 and 107 bp, respectively) was performed using the
LightCycler thermal cycler system (Roche Diagnostics, Burgess
Hill,West Sussex, UK) as previously described (19). The primers
used for theCRH-R1were:CRH-R1, 5-GGCAGCTAGTGGT-
TCGGCG-3 (sense) and 5-TCGCAGGCACCGGATGCTC-3
(antisense); CRH-R1, 5-GGCCAGGCTGCACCC ATTG-3
(sense), and 5-TCGCAGGCACCGGATGCTC-3 (antisense).
The quantification data were analyzed with the LightCycler
analysis software (Roche Diagnostics).
Cloning and sequence analysis
For sequencing purposes, DNA fragments were purified
from a 1.6% agarose gel by using QIAquick gel extraction kit
(QIAGEN, Crawley, West Sussex, UK) and sequenced using
internal primers for the whole gene in an automated DNA
sequencer, and the sequence data were analyzed using Blast
Nucleic Acid Database Searches from the National Center for
Biotechnology Information (Bethesda, MD).
The full-length CRH-R1 variant cDNAs were generated by
RT-PCRofhumanpregnantmyometrial cell polyRNAandwere
subsequently inserted into the plasmid pBluescript II SK (/)-
derived T vector and transformed into Escherichia coli strain
XL-1 Blue, and the positively selected clones were subcultured,
as previously described (13).
Transfection of HEK-293 cells
The cDNAs encoding CRH-R1 variants were subcloned in
pcDNA 3.1() (Invitrogen) HEK-293 cells, grown in DMEM,
and transiently transfected using Lipofectamine reagent (Life
Technologies) according to the manufacturer’s instructions.
Transfections were performed in 60-mm dishes (70% confluent
cells) with 8 g CRH-R1 plasmid cDNA and 16 g Lipo-
fectamine reagent. Receptor expression was allowed to proceed
for 24 h.
Western blot analysis and confocal microscopy of
CRH-R1 variant expression
Confluent HEK-293 transient expressing CRH-R1 variants
werewashedwith PBS and lysedwith 0.2%NaCl. The cellswere
homogenized in extraction buffer A [10 mM Tris-HCl, 1 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 mM MgCl2,
0.1% BSA, and 15 mM bacitracin (pH 7.2)] in Dulbecco’s PBS.
The homogenate was centrifuged at 600  g for 30 min at 4 C
to remove nuclei and unbroken cells. The supernatant was col-
lected and centrifuged at 40,000 g for 60min at 4C. The pellet
(50 g in 50 l aliquots) was rinsed twice and were solubilized
in 5 M urea-containing Laemmli buffer (0.17 M sodium dodecyl
sulfate; 0.4 M dithiothreitol; and 50 mM Tris-HCl, pH 8.0),
mixed, and placed in a boiling water bath for 5 min and allowed
to cool at room temperature.
Western blot analysis and immunofluorescent confocal mi-
croscopy in HEK-293 and human myometrial smooth muscle
cells using primary antibody for the CRH-R1/2 (Santa Cruz Bio-
technology) and a Leica model DMRE laser-scanning confocal
microscope (Leica Microsystems, Buckinghamshire, Milton,
Keynes, UK) with TCS SP2 scan head were carried out as pre-
viously described (14, 17).
Binding and second-messenger assays
Binding characteristics of 125I-oCRH using Scatchard anal-
ysis and cAMP, inositol phosphate, ERK1/2, and p38 MAPK
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stimulation assays of HEK-293 cells transfected with the differ-
ent CRH-R1 variants were carried out as previously described
(13, 14) in cells plated into 24-well plates at a density of 105
cells/well. cAMP production was measured using a cAMP RIA
kit (Biomedical Technologies Inc., Stoughton, MA).
Statistical analysis
Data are shown as the means  SEM of each measurement.
Data were tested for homogeneity and comparison between
group means was performed by one- or two-way ANOVA. P
0.05 was considered significant.
Results
Identification of a novel CRH-R1 variant mRNA in
human myometrium
Using specific RT-PCR primers to amplify CRH-R1
exon 6-containing cDNA sequences, twoDNA fragments
of 900and858bp, respectively,were amplified frompreg-
nant but not nonpregnant myometrial biopsies (Fig. 1A).
After nucleotide sequencing, the nucleic acid sequence of
the900 fragmentwas shown tobe identicalwith theCRH-
R1, whereas the nucleic acid sequence of the 858 frag-
mentwas shown to be identicalwith theCRH-R1 except
for an in-frame 42-bp deletion that corresponds to exon
13 of the human CRH-R1 and encodes 14 amino acids
(Gly385-Glu398) on the putative seventh TMD of the re-
ceptor protein, suggesting that this novel CRH-R1 splice
variant (termed CRH-R1/d) is generated by alternative
splicing of exon 13 but retention of exon 6 (characteristic
of theCRH-R1 sequence) (Fig. 1B).Hydropathyanalysis
of the amino acid sequences of the CRH-
R1 and CRH-R1/d receptors demon-
strated that the hydrophobic region corre-
sponding to the seventh TMD was smaller,
consistent with the predicted 14-amino acid
deletion (data not shown).
The length of the amplified nucleotide
sequence required to specifically detect
mRNA transcripts with exon 6 inclusion
and exon 13 excision prohibited the use of
real-time quantitative RT-PCR.Therefore,
CRH-R1/d mRNA expression in term or
preterm myometrium (31–40 wk of gesta-
tion) was investigated by a semiquantitative
RT-PCR assay. Results showed that CRH-
R1/d mRNA expression was highest in
early third-trimester myometrium (wk of
gestation) and progression toward term sig-
nificantly decreased expression (Fig. 2); in
contrast CRH-R1 mRNA expression lev-
els in nonlaboring myometrium remained
constant between 31 and 35 wk of gesta-
tion, whereas at termCRH-R1mRNA ex-
pression was significantly elevated, in agreement with our
previous data (17).
Cell expression, binding, and signal transduction
characteristics of the CRH-R1/d receptor
Expression of the variant CRH-R1/d receptorwas de-
termined in a transient transfectionHEK-293 cellular sys-
tem by using immunoblotting analysis to determine the
apparentmolecularweight of the CRH-R in plasmamem-
branes and compare protein expression in HEK-293 cells
transiently expressing CRH-R1 (293-R1) and CRH-
R1d (293-R1d) receptors. Fractionation of total cell ly-
sates by SDS-PAGE was performed and immunoblotting
using an antibody raised against a peptide corresponding
to amino acids 425–444 in the C terminus of the human
CRH-R1/2 precursor. Western blot analysis using the
CRH-R1/2 antibody in 293-R1, 293-R1d, or 293-R1/d
cell lysate preparations showed a single immunoreactive
protein with an apparent molecular mass of approxi-
mately 50 kDa (Fig. 3A). Using densitometric analysis, it
was shown that there was no significant difference in the
expression levels of all CRH-R variants tested, thus con-
firming that transfection efficiencieswere not different for
all CRH-R1 variants. No immunoreactive proteins were
detected in untransfected HEK-293 cells or when 1 M of a
synthetic CRH-R1 blocking peptide was added, thus con-
firmingthespecificityof thesedata(datanotshown). Indirect
fluorescent confocal microscopy using a specific CRH-R1/2
antibodywas alsoperformed todetermineCRH-R1/d sub-
FIG. 1. Identification of exon 6-positive CRH-R1 mRNA variants in human myometrium.
A, RT-PCR amplification of CRH-R1 variants sequences from RNA extracted from
nonpregnant (NP) or term pregnant (P) human myometrial biopsies. Specific primers
able to amplify exons 6–14 within CRH-R1 mRNA were used as described in Materials
and Methods. PCR products were resolved on 1.6% agarose gel and stained with
ethidium bromide. The identities of the fragments were confirmed by direct nucleotide
sequencing. The cDNA sequence has been submitted to the GenBank database
(identification no. 1367279). B, Schematic diagram of CRH-R1 and -R1/d exonic
sequence modifications and the predicted protein structure. Arrows indicate the
annealing position of PCR primers.
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cellular localization. Results (Fig. 3A, inset) showed signifi-
cant intracellularaccumulationof immunofluorescent signal
in CRH-R1/d-overexpressing cells with a weak plasma
membrane signal similar to R1d and in contrast to CRH-
R1-overexpressing cells that showed immunostaining that
was exclusively localized around the plasma membrane in
agreement with our previous data (15).
The binding characteristics of the novel CRH-R1 vari-
antweredeterminedusinga specific radioreceptor assay in
membranes prepared from293-R1/d cells and compared
with those of the 293-R1 and 293-R1d cells. Scatchard
analysis of 125I-oCRH binding for each of the CRH-R1
variants was consistent with the presence of a single pop-
ulation of high-affinity receptors; the CRH-R1/d and
CRH-R1 displayed identical binding affinity for CRH
with apparent dissociation constants (Kd) of 18.90 1.4
and 20.60  1.5 nM for CRH-R1/d and CRH-R1, re-
spectively. In contrast, the CRH-R1d exhibited signifi-
cantly higher binding affinity forCRH(2.20.7nM).The
maximum binding site concentrations (Bmax) in the
plasma membrane were significantly lower for the R1d
and R1/d variants compared with R1 (0.32  0.9 and
0.6  1.5 vs. 5.1  0.6 nmol/mg protein).
The signal transduction characteristics of the R1/d
receptors were also characterized and compared with
those of R1 and R1d. In both 293-R1 and 293-R1d
cells, CRH elicited a dose-dependent modest increase in
cAMP production with a threshold of 10 nM and maxi-
mum effect observed at CRH concentrations of 100 nM.
The maximum cAMP response ranged between 11  2-
and 16  3-fold above basal (Fig. 3B). However, in 293-
R1/d cells, the effect of CRH on adenylyl activation was
minimal and CRH was able to stimulate a weak cAMP
response only at concentrations greater than 1 M (3
1.3-fold above basal). In all types of cells, the integrity
of adenylyl cyclase was tested by the use of forskolin
(105 M), and no differences were found (data not
shown). Furthermore, HEK-293 cells expressing R1,
R1d, or R1/d variant receptors showed no increase in
inositol 1,4,5-triphosphate production or ERK1/2 and
p38 MAPK phosphorylation to CRH challenge (with
concentrations up to 1 M) (data not shown). Similar
results were obtained when Ucn1 was used as the stim-
ulating agonist (data not shown).
Steroid regulation of CRH-R1 variant mRNA
expression
Progression toward term is associated with alterations
in the E2-P4 balance that favor an increasingly estrogenic
FIG. 2. Determination of CRH-R1 and -R1/d mRNA expression
levels in human myometrium during the third trimester of pregnancy.
Representative autoradiograph (top panel) of CRH-R1 and -R1/d
mRNA sequence amplification by a semiquantitative RT-PCR as
described in Materials and Methods. PCR products were separated by
gel electrophoresis, and the dried gel was exposed to x-ray film. The
intensity of bands was quantified by the Microsoft Windows IQ
program after scanning of the screen (bottom panel). Data represent
the mean  SEM of three estimations from three independent
experiments. *, P  0.05 compared with values obtained at 31 wk.
FIG. 3. Expression and signaling characteristics of CRH-R1/d
expressed in HEK-293 cells. A, Cell lysates from HEK-293 cells
(untransfected-NC) or transiently expressing CRH-R1 or CRH-R1d or
CRH-R1/d were prepared, and 50 g of protein was fractionated on
SDS-PAGE and subjected to immunoblotting with specific antibodies
against CRH-R1/2 or total ERK1/2. Antibody complexes were detected
by enhanced chemiluminescence. Inset, CRH-R1/d subcellular
localization was assessed by indirect confocal microscopy. HEK-293
cells transiently expressing CRH-R1/d were grown on poly-D-lysine-
coated glass cover slips. Receptor immunoreactivity was detected with
a RH-R1/2-specific antibody and Alexa Fluor 594 secondary antibody.
Identical results were obtained from three independent experiments.
WB, Western blot. Scale bar, 30 m. B, cAMP release from HEK-293
cells transiently expressing CRH-R1/d or its parent receptor variants
CRH-R1 or CRH-R1d in the presence of different concentrations of
CRH. Results are representative of one receptor clone and are
expressed as the mean six SEM of four estimations from three
independent experiments. *, P  0.05 compared with basal.
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environment (20). To investigate potential effects of ste-
roid hormones on the mRNA expression of R1 and
R1/d variants, human myometrial smooth muscle cells
isolated from pregnant term nonlaboring myometrium
andcultured inhormonedepleted serumwere treatedwith
or without 5 M of E2 or P4 or both. Under basal condi-
tions only the CRH-R1 mRNA was detected (Fig. 4).
Treatment of cells with E2 for 12 h resulted in a 4-fold
decrease in the amount of CRH-R1mRNA, and this was
associated by a substantial up-regulation of exon 13-neg-
ative CRH-R1/d mRNA transcripts. In E2-treated myo-
metrial cells, the CRH-R1/d appeared to be the predom-
inant exon 6-containing CRH-R1 variant mRNA. The
effects of E2 on CRH-R1 and R1/d mRNA transcripts
was found to be time dependent and were apparent 6 h
after the start of the hormonal treatments and were sus-
tained for at least 24 h (data not shown). Similar effects
were observed when E2 was used at a concentration range
of 0.5–5 M; however, 5 M E2 produced the most con-
sistent responses and was used in all subsequent experi-
ments (data not shown).
Treatment of myometrial cells with E2 in the presence
of P4 markedly decreased E2 effects on CRH-R1/d
mRNA expression but increased CRH-R1mRNA tran-
scripts. In these cells the CRH-R1 appeared to be the
predominant exon 6-containingCRH-R1 variantmRNA.
Treatment ofmyometrial cells with P4 alone substantially
increased CRH-R1 mRNA transcripts (Fig. 4A), thus
confirming P4 actions on stimulating CRH-R1 mRNA
expression. Interestingly, an apparent up-regulation in
both exon 13-positive (CRH-R1) and -negative (CRH-
R1/d)R1variantmRNAswas evident in P4-treated cells,
raising the possibility of stimulatory effects at the level of
the CRHR1 promoter.
To investigate whether P4 specifically targeted exon 6
positive (CRH-R1 and CRH-R1/d) mRNA transcripts
or was able to influence expression of other CRH-R1
mRNAtranscripts, real-timeRT-PCRwasused to analyze
expression of exon 6-negative CRH-R1 mRNA tran-
scripts, such as the CRH-R1 mRNA. Indeed, we identi-
fied a significant increase by 3-fold of exon 6-negative
CRH-R1 mRNA transcripts after P4 treatment (Fig. 5A).
We also used indirect confocal immunofluorescent mi-
croscopy studies to investigate potential changes in
CRH-R subcellular localization in P4-treated cells (Fig.
5B). These studies failed to detect any significant changes
in distribution of CRH-R immunofluorescent signal in re-
sponse to P4 treatment, although the overall CRH-R im-
munoreactivity appeared enhanced in P4-treated cells.
Given that the principal exon 6-negative CRH-R1
mRNA transcript encodes for the fully active CRH-R1,
we also investigated the possibility that P4pretreatment of
myometrial cells alters cellular responsiveness to the ac-
tions of CRH and stimulation of downstream signaling
events. After P4 pretreatment, the ability of the myome-
trial cells to increase intracellular cAMP levels in response
to CRH (1–100 nM) was significantly enhanced by 2- to
4-fold (Fig. 6A). There was no differences in forskolin-
stimulated cAMP levels between control and P4-treated
cells, thus excluding direct effects of P4 treatment on ad-
enylyl cyclase activity. Moreover, this P4 effect was asso-
ciated with changes in the binding characteristics and
number of CRH-R present in myometrial cells; Scatchard
analysis of 125I-oCRH binding in membranes prepared
from myometrial smooth muscle cells demonstrated that
after P4pretreatment,CRHbindingaffinitywas increased
with apparentKds of 5.302.4 and1.60.9 nMwithout
or with P4 pretreatment, respectively. P4 pretreatment re-
sulted in a 6- to 10-fold increase in the high-affinity bind-
ing sites and an increase in the Bmax from 8  5.9 and
65  36 pmol/mg protein.
Because we previously identified that exon 6 plays a
major role in determining the response of individual
CRH-R1 variants to protein kinase C (PKC) phosphory-
lation and heterologous desensitization (15), we investi-
gated whether P4 effects on CRH-R1 mRNA expression
can altermyometrial CRH-R responses to PKCphosphor-
ylation. After pretreatment with P4 or vehicle for 24 h,
FIG. 4. Effect of E2 and progesterone on CRH-R1 and CRH-R1/d
mRNA expression levels in human myometrial smooth muscle cells.
RNA was extracted from cells pretreated with 5 M of E2 or P4 or both
for 12 h, and CRH-R1 and R1/d mRNA sequence were amplified by
a semiquantitative RT-PCR as described in Materials and Methods. PCR
products were separated by gel electrophoresis and the dried gel was
exposed to x-ray film. A representative autoradiograph is shown in the
top panel. The intensity of bands was quantified by the Microsoft
Windows IQ program after scanning of the screen (bottom panel).
Data represent the mean  SEM of three estimations from three
independent experiments. *, P  0.05 compared with control
[untreated (NS, Nonstimulated)] cells.
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cells were treated for 30 min with or without phorbol
12-myristate 13-acetate (PMA) or the inactive phorbol
ester 4-phorbol-12,13-didecanoate (4-PDD) followed
by addition of 10M forskolin or 100 nMCRH for 10min
andestimationof cAMPproduction. In control cells PMA,
but not 4-PDD, significantly impaired by 40–50% the
ability of CRH to stimulate intracellular cAMP produc-
tion, suggesting that the myometrial cell CRH-Rs were
sensitive to PKC activation (Fig. 6A). In contrast, this ef-
fectwas abolished in cells pretreatedwithP4. Inboth types
of cells (control or P4 pretreated), basal and forskolin-
induced cAMP production was not significantly altered
after PMA treatment (data not shown).
Discussion
Critical physiological and pathophysiological steps of
pregnancy, such as embryo implantation, fetal immune
tolerance, and parturition, are regulated by CRH (21).
Expression of CRH-R1 and -R2 receptors in the human
myometrium enables CRH and CRH-like peptides to
modulate myometrial contractility during pregnancy and
labor by exerting distinct and possibly contrasting effects
(6, 22). In particular, the CRH-R1 subtype, which medi-
ates the inhibitory effects of CRH on myo-
metrial contractility through activation of
the cAMP/adenylyl cyclase and nitric oxide
pathways (22, 23), is extensively targetedby
alternative pre-mRNA splicingmechanisms
that generate a plethora of CRH-R1 splice
variants that might contribute in the con-
siderable CRH-R protein heterogeneity ob-
served in humanmyometrium (24). The ex-
pression of these receptor variants, which
might act as decoy or dominant-negative re-
ceptors (11), is dynamicallymodulated dur-
ing pregnancy and labor (17), thus allowing
the myometrial tissue to adjust its respon-
siveness to CRH according to specific re-
quirements during the different stages of
pregnancy and labor.
Here we report the identification of a
novel myometrial CRH-R1 splice variant
(CRH-R1/d), which has exon 13 removed
but retains the R1-specific exon 6, thus re-
sulting in a final mRNA transcript that is a
hybrid betweenCRH-R1 and -R1d.When
overexpressed in HEK-293 cells, the CRH-
R1/d was primarily localized intracellu-
larly and to a lesser degree in the plasma
membrane (similar to CRH-R1d) and has
reduced binding affinity for CRH (a char-
acteristic of the CRH-R1). No significant activation of
known intracellular signaling pathways was detected,
probably due to the impact of combined structural mod-
ifications (retention of 29 amino acids in the IC1 and de-
letion of 14 amino acids from TMD7) that impair
CRH-R1 signal transduction. The identification of such a
CRH-R1 mRNA variant suggests the presence of specific
splicing mechanisms controlling excision or inclusion of
exon 13 independently of exon 6 from the final mRNA
transcript. These mechanisms appears to be pregnancy
specific and active in the early stages of the third trimester
of humanpregnancybecause, similar toourprevious stud-
ies onCRH-R1dmRNAexpression (17), the CRH-R1/d
mRNAwas identified in human pregnant (term as well as
preterm) but not nonpregnant myometrium. Further-
more, exon 6-containing CRH-R1 mRNA transcripts
have been identified in other tissues including the pituitary
(8), mast cells (25), and endometrium (26), raising the
possibility that CRH-R1/d mRNA is also expressed in
these tissues.
The alternative pre-mRNA splicing mechanisms regu-
lating generation of CRH-R1 variants are unknown.
Pisarchik and Slominski (27) reported that in the mela-
nomacell line SKMEL188, environmental challenges such
FIG. 5. P4 effects on CRH-R1 exon 6() mRNA expression and CRH-R subcellular
localization in human myometrial smooth muscle cells. A, Representative maxima of
melting curves of CRH-R1 exon 6() mRNA transcripts amplified from RNA extracted
from cells pretreated with or without 5 M of P4 for 12 h by real-time quantitative RT-
PCR (LightCycler; Roche Diagnostics) as described in Materials and Methods. PCR
products were electrophoresed on a 1.6% agarose gel. Apart from using the standard
curve analysis, quantitation was also carried out, using melting curve analysis.
Correction of the amplification curves was carried out by taking a melting curve at the
end of the amplification and then calculating the area under the specific product peak,
which is related to the amount of product melting at that temperature. B, Effect of 5
M P4 pretreatment for 12 h on CRH-R immunostaining distribution in human pregnant
myometrial cells visualized by indirect immunofluorescence confocal microscopy using
specific primary antibodies for CRH-R and Alexa Fluor 594 secondary antibody (red) as
described in Materials and Methods. Distribution of F-actin and stress fibers was also
monitored by double staining with Alexa Fluor 488-phalloidin (green). Cell nuclei were
stained with the DNA-specific dye 4,6-diamino-2-phenylindole (blue). Identical results
were obtained from six independent experiments.
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as UV irradiation as well as activation of Ser/Thr protein
kinases A andC, promote exon 13 retention in themature
CRH-R1 mRNA transcript. Our studies in human pri-
mary myometrial smooth muscle cells suggest that estro-
gens such as E2 is a potent inducer of exon 13 skipping
from the final CRH-R1 mRNA transcript. This result
might be physiologically relevant and is in line with our
previous studies (17) that demonstrated increased expres-
sion of exon 13-negative CRH-R1 mRNA transcripts in
laboring (term or preterm) myometrium, which exhibit
increased responsiveness to E2. A major determinant of
myometrial sensitivity to actions of estrogens is P4; it has
been proposed (28) that P4 prorelaxation effects for most
of pregnancy involve inhibition of estrogen receptor- ex-
pression and decreased myometrial sensitivity to estro-
gens. This would explain why the human myometrium is
refractory to the high levels of circulating estrogens for
most of pregnancy. At term the functional P4withdrawal,
mediated by an increase in the myometrial PR-A to PR-B
expression ratio (29), results in removal of progesterone
actions on estrogen receptor- expression and increases
myometrial responsiveness to estrogens that act to trans-
form themyometrium to a procontractile phenotype. This
apparent interplay between E2 and P4 signaling appears
also to be important for the control of CRH-R1 splice
variant expression because our studies showed that the
E2 effect on exon 13 skipping was significantly attenu-
ated in the presence of progesterone. Inter-
estingly, in the primary myometrial cellular
model, P4 alone increased expression of
exon 6-positive CRH-R1 mRNA variant
(primarilyCRH-R1andalsoCRH-R1/d)
as well as exon 6-negative CRH-R1 mRNA
variants such as CRH-R1, raising the pos-
sibility of a different mode of action target-
ing theCRHR1promoter.This possibility is
supported by previous studies using in silico
analysis that identified a progesterone re-
sponse element within the CRHR1 pro-
moter region (30); however, more detailed
studies are required to confirm this.
It is becoming increasingly evident that
CRH exerts an inhibitory effect on contrac-
tility of nonlaboring, but not laboring, term
myometrium, and this effect involves acti-
vation of the CRH-R1 (31, 32). Recently it
has been shown that P4 pretreatment can
augment CRH actions on myometrial qui-
escence, suggesting synergistic effects (33).
Our studies on the Kd and Bmax binding
characteristics of CRH-R suggest that pro-
gesterone effects on myometrial CRH-R1
mRNAexpression lead to increasedamount
of high-affinity CRH-R binding sites in the plasma mem-
brane that augment myometrial cell responsiveness to
CRH and generation of intracellular signals such as
cAMP, which is the main downstream effector in myo-
metrium during pregnancy. In addition, progesterone ap-
pears to up-regulateCRH-R1 variants that are resistant to
PMA-induced PKCactivation.We have previously shown
(15) that CRH-R1 and CRH-R1 variants exhibit dif-
ferential responses to PKC-induced phosphorylation,
with only the exon 6-positive CRH-R1 susceptible to
signaling desensitization. Taken together, these results
suggest that progesterone primarily increases CRH-R1
expression and thus promotes amyometrial CRH-R1 sys-
tem with reduced sensitivity to heterologous desensitiza-
tion by PKC. The progesterone-driven regulation of
CRHR1 expressionmight be active in pregnant nonlabor-
ing myometrium to maintain myometrial quiescence; at
termandduring labor, P4 effectsmight diminishdue to the
functional progesterone withdrawal, and CRHR1 gene
expression levels might be controlled by other contrac-
tion-activating signals like IL-1 (17).
In conclusion, we have identified a novel CRH-R1
mRNA variant (CRH-R1/d) generated by alternative
splicing of exon 13 but retaining the R1-specific exon 6,
thus resulting in a final mRNA transcript that is a hybrid
between CRH-R1 and -R1d. CRH-R1/d mRNA is
FIG. 6. P4 effects on CRH-induced cAMP response in human myometrial smooth
muscle cells and regulation by PKC. A, Effect of P4 on CRH-induced cAMP production
from human pregnant myometrial cells. Cells were pretreated with P4, followed by
incubation with 0.1–100 nM CRH for 10 min. Results are representative of four
independent cell culture preparations. Each point is the mean  SEM of four estimates.
*, P  0.05 compared with basal; , P  0.05 compared with CRH-stimulated values in
cells without P4 pretreatment. B, Effects of PKC activation on CRH-induced cAMP
production in human myometrial smooth muscle cells pretreated with or without P4.
After pretreatment with or without 5 M of P4 for 12 h, cells were incubated with 200
nM PMA or 500 nM 4-PDD for 30 min before subsequent stimulation with 100 nM CRH
for 10 min and determination of cAMP production as described under Material and
Methods. Results were normalized by expressed as percentage of forskolin-induced
cAMP release, which was considered as maximum (100%) for each group (treated or
untreated). Results are presented as the mean  SEM of five estimations from four
individual experiments. *, P  0.05 compared with control (PKC naïve untreated) cells.
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present in pregnant but not nonpregnant myometrium,
and inhumanprimarymyometrial smoothmuscle cells, its
expression is regulated by E2. The translated protein re-
ceptor variant exhibits structural and functional charac-
teristics similar to CRH-R1 and -R1d such as mainly
cytoplasmic localization reduced ligand binding affinity
and negligible signaling. We also showed that P4 appears
to be a potent inducer of exon 6-positive (CRH-R1) and
exon 6-negative (CRH-R1) CRH-R1 mRNA variants;
this leads to increased myometrial cell responsiveness to
the actions of CRH. During pregnancy this mechanism
might enable the myometrial microenvironment to main-
tain relaxation.
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